|
Wuhan Keqian Biology Co., Ltd (688526.SS) Évaluation DCF
CN | Healthcare | Biotechnology | SHH
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Wuhan Keqian Biology Co.,Ltd (688526.SS) Bundle
Prenez en charge votre analyse d'évaluation de votre Wuhan Keqian Biology Co., Ltd (688526SS) avec notre calculatrice avancée DCF! Préchargé avec des données réelles (688526SS), ce modèle Excel vous permet d'ajuster les prévisions et les hypothèses pour calculer avec précision la valeur intrinsèque de Wuhan Keqian Biology Co., Ltd.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 507.5 | 843.2 | 1,103.0 | 1,001.3 | 1,064.1 | 1,314.2 | 1,623.0 | 2,004.4 | 2,475.5 | 3,057.3 |
| Revenue Growth, % | 0 | 66.15 | 30.81 | -9.22 | 6.27 | 23.5 | 23.5 | 23.5 | 23.5 | 23.5 |
| EBITDA | 290.2 | 557.5 | 638.3 | 569.9 | 580.4 | 769.1 | 949.9 | 1,173.1 | 1,448.8 | 1,789.3 |
| EBITDA, % | 57.19 | 66.11 | 57.87 | 56.92 | 54.54 | 58.53 | 58.53 | 58.53 | 58.53 | 58.53 |
| Depreciation | 37.1 | 37.0 | 62.6 | 97.7 | 114.5 | 99.6 | 123.0 | 152.0 | 187.7 | 231.8 |
| Depreciation, % | 7.32 | 4.39 | 5.68 | 9.76 | 10.76 | 7.58 | 7.58 | 7.58 | 7.58 | 7.58 |
| EBIT | 253.1 | 520.4 | 575.7 | 472.2 | 465.9 | 669.5 | 826.8 | 1,021.2 | 1,261.1 | 1,557.5 |
| EBIT, % | 49.87 | 61.72 | 52.19 | 47.16 | 43.78 | 50.94 | 50.94 | 50.94 | 50.94 | 50.94 |
| Total Cash | 671.0 | 2,184.0 | 768.3 | 1,130.9 | 1,326.8 | 1,234.4 | 1,524.5 | 1,882.8 | 2,325.3 | 2,871.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 101.8 | 187.1 | 326.5 | .0 | 343.1 | 273.6 | 337.9 | 417.3 | 515.4 | 636.5 |
| Account Receivables, % | 20.05 | 22.19 | 29.6 | 0 | 32.25 | 20.82 | 20.82 | 20.82 | 20.82 | 20.82 |
| Inventories | 62.9 | 71.1 | 108.8 | 169.4 | 144.8 | 160.9 | 198.7 | 245.4 | 303.1 | 374.3 |
| Inventories, % | 12.39 | 8.43 | 9.87 | 16.92 | 13.61 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 |
| Accounts Payable | 105.5 | 145.5 | 215.7 | 244.3 | 132.3 | 248.2 | 306.5 | 378.6 | 467.6 | 577.4 |
| Accounts Payable, % | 20.79 | 17.25 | 19.56 | 24.4 | 12.44 | 18.89 | 18.89 | 18.89 | 18.89 | 18.89 |
| Capital Expenditure | -137.7 | -111.6 | -374.4 | -102.9 | -104.5 | -248.1 | -306.5 | -378.5 | -467.4 | -577.3 |
| Capital Expenditure, % | -27.14 | -13.23 | -33.95 | -10.27 | -9.82 | -18.88 | -18.88 | -18.88 | -18.88 | -18.88 |
| Tax Rate, % | 13.47 | 13.47 | 13.47 | 13.47 | 13.47 | 13.47 | 13.47 | 13.47 | 13.47 | 13.47 |
| EBITAT | 220.7 | 448.5 | 497.8 | 414.4 | 403.1 | 581.3 | 717.9 | 886.6 | 1,095.0 | 1,352.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 60.9 | 320.3 | 79.1 | 703.8 | -17.4 | 602.1 | 490.7 | 606.0 | 748.4 | 924.3 |
| WACC, % | 7.25 | 7.25 | 7.25 | 7.25 | 7.25 | 7.25 | 7.25 | 7.25 | 7.25 | 7.25 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 2,696.4 | |||||||||
| Long Term Growth Rate, % | 3.00 | |||||||||
| Free cash flow (T + 1) | 952 | |||||||||
| Terminal Value | 22,410 | |||||||||
| Present Terminal Value | 15,793 | |||||||||
| Enterprise Value | 18,490 | |||||||||
| Net Debt | -288 | |||||||||
| Equity Value | 18,778 | |||||||||
| Diluted Shares Outstanding, MM | 466 | |||||||||
| Equity Value Per Share | 40.31 |
Benefits of Working with Wuhan Keqian Biology Co., Ltd (688526SS)
- Pre-Loaded Financial Model: Utilize Wuhan Keqian's actual data for accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth rates, profit margins, WACC, and other essential parameters.
- Real-Time Calculations: Instantaneous updates allow you to view results immediately as you make adjustments.
- Investor-Ready Template: A polished Excel file crafted for high-quality professional valuation.
- Flexible and Repeatable: Customizable for various scenarios, enabling thorough and repeated forecasting.
Key Features
- Comprehensive Historical Data: Access Wuhan Keqian Biology Co., Ltd’s (688526SS) financial statements and pre-filled forecasts.
- Customizable Parameters: Modify inputs such as WACC, tax rates, revenue growth, and EBITDA margins to suit your analysis.
- Real-Time Valuation: Watch the intrinsic value for Wuhan Keqian Biology Co., Ltd (688526SS) update instantly as you adjust inputs.
- Intuitive Visualizations: Utilize dashboard charts to present valuation outcomes and critical metrics clearly.
- Designed for Precision: A robust tool crafted for analysts, investors, and finance professionals.
How It Functions
- Step 1: Download the Excel file.
- Step 2: Examine the pre-filled data for Wuhan Keqian Biology Co.,Ltd (688526SS), including historical and projected figures.
- Step 3: Modify the key assumptions (highlighted in yellow) according to your analysis.
- Step 4: Observe the automatic recalculations for the intrinsic value of Wuhan Keqian Biology Co.,Ltd (688526SS).
- Step 5: Utilize the results for your investment decisions or reporting needs.
Why Opt for This Calculator?
- All-in-One Solution: Features DCF, WACC, and comprehensive financial ratio analyses in a single platform.
- Flexible Inputs: Modify the yellow-highlighted fields to explore various scenarios.
- In-Depth Analysis: Automatically computes Wuhan Keqian Biology's intrinsic value and Net Present Value.
- Data Ready: Comes with historical and forecast data for precise baseline calculations.
- Professional Standard: Tailored for financial analysts, investors, and business consultants.
Who Can Benefit from This Product?
- Professional Investors: Create comprehensive and trustworthy valuation models for investment analysis of Wuhan Keqian Biology Co., Ltd (688526SS).
- Corporate Finance Teams: Examine valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation assessments for clients interested in Wuhan Keqian Biology Co., Ltd (688526SS).
- Students and Educators: Utilize up-to-date data to practice and instruct on financial modeling techniques.
- Biotech Enthusiasts: Gain insights into how biotech firms like Wuhan Keqian Biology Co., Ltd (688526SS) are valued within the industry.
What the Template Includes
- Historical Data: Comprises Wuhan Keqian Biology's previous financial performance and baseline projections.
- DCF and Levered DCF Models: Comprehensive templates to determine the intrinsic value of Wuhan Keqian Biology (688526SS).
- WACC Sheet: Pre-calculated metrics for the Weighted Average Cost of Capital.
- Editable Inputs: Adjust critical factors such as growth rates, EBITDA margins, and CAPEX estimates.
- Quarterly and Annual Statements: A thorough analysis of Wuhan Keqian Biology's financial data.
- Interactive Dashboard: Dynamically visualize valuation outcomes and forecasts.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.